Tuberculous meningitis (TBM) is the most lethal and Background: disabling form of tuberculosis. Delayed diagnosis and treatment, which is a risk factor for poor outcome, is caused in part by lack of availability of diagnostic tests that are both rapid and accurate. Several attempts have been made to develop clinical scoring systems to fill this gap, but none have performed sufficiently well to be broadly implemented. We aim to identify and validate a set of clinical predictors that accurately classify TBM using individual patient data (IPD) from published studies.
Introduction
Tuberculosis remains a major global health problem, with the most lethal and disabling form being tuberculous meningitis (TBM), of which there are more than 100,000 new cases each year 1 . Mortality is high, particularly in children and patients who are co-infected with HIV-1 2 . The diagnosis is often delayed by the insensitive and lengthy culture technique required for disease confirmation, with delayed diagnosis and treatment being important risk factors for poor outcome 1 . Recently introduced nucleic acid amplification tests (NAATs) allow more rapid detection of TBM. Pooled specificity of 98.0% and 90% for Xpert MTB/RIF and Xpert MTB/RIF Ultra respectively, suggest that they are effective rule-in tests with the potential to speed up diagnosis and reduce unnecessary treatments for alternative conditions in some patients. However, the pooled sensitivity is 71.1% and 90% respectively, which is even lower for patients with HIV (58% to 81%) 3 . Given the extremely high mortality if treatment is withheld from patients with TBM, these values are unlikely to be sufficient evidence to withhold treatment when negative in most patients. Improved strategies to rapidly and accurately diagnose TBM are urgently needed 1 .
A major stumbling block in TBM research had been the absence of a single reference standard test or standardised diagnostic criteria. In 2010, a committee of 41 international experts in the field developed consensus case definitions for TBM for use in clinical research 4 . These case definitions have helped to standardise research but are not appropriate for use in routine clinical care as they depend on variables such as cerebrospinal fluid (CSF) culture results, which can take up to 6 weeks to become positive and may include brain imaging, which is not available in many resource constrained settings.
Another approach to improving rapid diagnosis in TBM, particularly in resource-limited settings where the majority of cases occur, is to develop and validate multivariable prediction models. At least 10 models have been published for the diagnosis of TBM, but a major limitation is that their performance is variable in different populations and settings 1 . A major reason for heterogeneous model performance across different settings and populations is case mix variation, which refers to the distribution of important predictor variables such as HIV status and age, and the prevalence of TBM. Case mix variation across different settings or populations can lead to genuine differences in the performance of a prediction model, even when the true predictor effects are consistent (that is, when the effect of a particular predictor on outcome risk is the same regardless of the study population) 5 .
Recent studies have shown how big datasets can be used to examine heterogeneity and improve the predictive performance of a model across different populations, settings, and subgroups [6] [7] [8] . Individual patient data meta-analysis is preferred to aggregate data meta-analysis, as risk scores can be generated and validated, and multiple individual level factors can be examined in combination 9 .
Objectives
1. Conduct a systematic review to identify studies that applied systematic diagnostic strategies for TBM in adolescents and adults presenting with meningitis 2. Establish an international collaboration among TBM research groups who are willing to provide individual patient data (IPD)
3. Use IPD to develop a clinical prediction model that estimates the probability of TBM in adolescent and adults, based on clinical and laboratory data that is routinely available within 48 hours of initial evaluation
Secondary objectives include an assessment of the number and quality of studies addressing the diagnosis of TBM, as well as an analysis of demographic and clinical characteristics of cases and non-cases of TBM.
Protocol
A systematic review and IPD meta-analysis will be performed according to Preferred Reporting Items for Systematic review and Meta-Analysis of IPD (PRISMA-IPD) guidelines 10 .
Identification of studies
Potentially eligible studies will be identified by an extensive search of electronic databases, manual search of reference lists and by contacting researchers with interest and expertise in meningitis who may have access to unpublished studies.
We have designed a broad search strategy to maximise sensitivity. We will combine medical subject heading (MeSH) and free text terms to identify relevant studies, see Table 1 . We will search Medline (accessed via PubMed), Africa-Wide Information and CINAHL (both accessed via EBSCO Host). We will not limit our searches by geographical location. The search will be restricted to studies published after 01 January 1990 and in English. The detailed search strategies will be presented in an online supplementary appendix. Reference lists of the selected articles and reviews will be searched manually to identify additional relevant studies.
Types of studies

Inclusion criteria
• Randomized controlled trials, cross-sectional studies, and observational cohort studies
• Participants presenting to care with clinical meningitis
• Use of at least 1 of microscopy for acid-fast bacilli, commercial nucleic acid amplification test (NAAT) for Mycobacterium tuberculosis or mycobacterial culture of CSF to diagnose TBM
• Study includes a minimum of 10 participants aged ≥ 13 years
Amendments from Version 1
Anna Stadelman has completely re-written the data synthesis section following the reviewer comments.
Any further responses from the reviewers can be found at the end of the article
REVISED
Exclusion criteria
• Case-control studies and case reports/series of patients with confirmed TBM
• Participants taking anti-TB drugs at the time of their evaluation
• Non-English articles
• Studies published before 1990
• Full text unable to be located
• Studies not in humans
Screening and study selection Duplicate studies will be removed. Study selection will follow the process described in the Cochrane Handbook of Systematic Reviews and PRISMA-IPD statements 10 . Two investigators will independently screen titles and abstracts to remove irrelevant studies. Full text review will be performed on the remaining studies to determine eligibility. Any disagreements will be resolved by consensus or in consultation with a third reviewer.
Data extraction
Data will be extracted on a proforma, independently by two review authors on study level variables: study setting and dates; contact details; inclusion criteria and exclusion criteria, and number of patients. Corresponding authors of studies identified as eligible after full text review will be contacted with a request to provide anonymised individual patient data. IPD for variables that have previously been shown to be predictive of TBM 1 and competing diagnoses will be requested, Table 2 . Investigators will be requested to share their anonymised data after obtaining a signed agreement.
Data management
Investigators will be asked to share anonymised individual patient data, preferably electronically using encrypted files and other secure data transfer technologies using standardised data collection forms. Only study collaborators will have access to the combined IPD data available in Box. Box Secure Storage is a cloud storage and collaboration service configured to meet the security standards for HIPAA data. Data will remain stored in Box for the duration of the study and will not be used or sold for any commercial purpose.
Authorship
Authors providing IPD will be asked to nominate co-authors to expand the expertise of the review group, including review of preliminary findings and manuscript authorship. The number of co-authors will depend on the amount of data supplied, 1 author for <100 patients, 2 authors for >100 and <250 patients, and 3 authors for >250 patients.
Quality assessment
Quality assessment in terms of risk of bias and applicability for each included study will be performed according the QUADAS-2 tool for diagnostic accuracy studies 11 . This tool comprises 4 domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed in terms of risk of bias, and the first 3 domains are also assessed in terms of 
Data Synthesis
1. Descriptive analysis of available parameters, data completeness check, and IPD meta-analysis.
The contributing datasets will be reviewed for sample size, available parameters and data completeness, to inform the selection of a modelling approach. A descriptive analysis will be undertaken to understand similarities and differences between the contributing datasets. Participant characteristics and clinical features (Table 1) will be summarized for each contributing dataset and compared across datasets using chi-square, t-tests, or non-parametric methods as warranted. Then, we will formally evaluate case-mix variation and predictor heterogeneity via IPD meta-analysis using a logistic regression model with stratified intercepts for each study 7 . Each TBM predictor will be rotated into the model individually to underscore the baseline predictive value of each in the different contributing datasets. We will also use this method to assess predictor heterogeneity by HIV status, WHO region, and TB burden within each country.
Cluster Analysis
Clustering in the data will be explored using a variety of methods including Gaussian Mixture Models and cluster analysis (latent component analysis (LCA), Spectral Clustering, KMeans). This step serves as a tool to elucidate case-mix variation within TBM diagnostic categories (confirmed, probable, possible/suspected, and not-TBM), which will inform TBM diagnostic prediction and TBM prediction model development.
Data Reduction
The objective of this step will be to reduce the number of variables that go into the development of the TBM prediction model. This step is motivated by the intention to retain variables that are most predictive of TBM diagnosis and that are easily acquired in low resource settings. We will employ methods such as principle component analysis and joint individual variation explained 12 to identify the varaibales that explain most of the variation in TBM diagnosis to retain in the final model(s).
Developing a Predictive Model
All the data collected from the systematic review will be used in the development of the clinical prediction tool. The objective of this step is to develop and evaluate several clinical prediction tools using different approaches, with the goal of selecting the most efficient and discriminatory tools to internally validate. The clinical prediction tool(s) will be developed using machine learning techniques including classification and regression trees and random forest classifier analysis.
Testing the model for internal validity
The model(s) will be internally validated using the bootstrap, cross-validation, and internal-external cross validation approaches. Bootstrap validation is the process for which observations from the original dataset are sampled with replacement to go into the development of the model, the model development analyses are repeated, and then this model is internally validated in the observations from the original dataset that were not chosen 13, 14 . Cross-validation is the process for which the prediction model is developed in most of the dataset and tested on a random part of the dataset that was left out from the sample 13 . Internal-external cross validation approach is a multiple validation approach that accounts for multiple studies by rotating which are used toward model development and validation 7 . Each contributing study will be excluded from the available set, and the remainder will be used to develop the diagnostic model; the excluded study will then be used to validate the model externally. This process will be repeated with each study being omitted in turn, allowing the consistency of the developed model and its performance to be examined on multiple occasions.
Performance of the developed model(s) will be assessed using metrics for optimism, calibration, and discrimination. Optimism is defined as how well the model fits the data, which is how we assess "overfitting" where the model fits the data so well that it is not valid for new subjects, a key threat to internal validity that needs to be addressed thorughout the internal validation process. For the bootstrap approach, optimism is estimated as true performance minus apparent performance, where true performance refers to the c-statistic generated from the original dataset, and apparent performance refers to the estimated performance in the bootstrap sample 15 . We then calculate the difference in the true and apparent probabilities for each bootstrap sample, and take the average across many, typically 100-200 times 16 . For the cross-validation approach, optimism will be estimated as the average of all (k-fold) assessments. For the internal-external cross validaiton approach, optimism will be estimated in each study that is excluded from development.
As discussed, high optimism is indicative of overfitting, which can be corrected via shrinkage. Shrinkage is defined as the regression of coefficients towards zero as a way to drop unnecessary predictors and improve model performance 15 . Although we do not anticipate that we will need to employ this method to correct for overfitting because we will have completed the data reduction step described in step 3 above, we will validate the necessity of the shrinkage approach when assessing model optimism.
Calibration is defined as the agreement between observed outcomes and predictions 15 . For the bootstrap approach, calibration will be estimated as true calibration minus apparent performance, where true performance refers to the agreement between observed outcomes and predictions generated from the original dataset, and apparent performance refers to the agreement between observed outcomes and predictions generated from in the bootstrap sample 15 . We then calculate the difference in the true and apparent agreements for each bootstrap sample, and take the average across many, typically 100-200 times 16 . For the cross-validation approach, calibration will be estimated as the average of all (k-fold) agreements. For the internal-external cross validaiton approach, calibration will be estimated in each study that is excluded from development.
Calibration is also related to goodness-of-fit, which relates to the ability of a model to fit a given set of data 15 . The HosmerLemeshow goodness-of-fit test is often used to assess goodness-of-fit with binary outcome data, which can be graphically displayed in a calibration plot. Usually, patients are grouped by decile of predicted probability. A better calibrated model has more spread between such deciles than a poorly calibrated model 15 .
Discrimination is defined as the ability to generate predictions that discriminate between those with and those without the outcome (e.g. TBM vs not-TBM diagnosis) 15 . We can assess discrimination using a receiver operating characteristic (ROC) curve, which plots the sensitivity (true positive rate) against 1 -specificity (false-positive rate) for consecutive cutoffs for the probability of an outcome (i.e. TBM diagnosis). For both the bootstrap and cross-validation approaches, ROC curves will be produced as an average for the models that are bootstrapped/crossvalidated and discrimination will be compared using the area under the curve (AUC) metric. For the internal-external cross validaiton approach, calibration will be estimated in each study that is excluded from development. The AUC can be interpreted as the probability that a patient with the outcome is given a higher probability of the outcome by the model than a randomly chosen patient without the outcome 15 . The higher the AUC, represented by the curve closer to the upper lefthand corner (higher sensitivity and specificity), the better the model is at predicting the outcome, in this case TBM diagnosis. Furthermore, ROC curves are often used in diagnostic research to quantify the diagnostic value of a test over its whole range of possible cutoffs for classifying patients as positive vs. negative 15 . The curves trend to the upper left corner when the distributions of predictions are more separate between those with and without the outcome.
In addition to assessing model optimism, calibration, and discrimination, the Brier score will be used to assess overall model performance. The Brier score measures the accuracy of probabilistic predictions, which is a combination of both calibration and discrimination 15, 17 . The Brier score calculates the squared differences between actual outcomes and predictions. For a model, the Brier score can range from 0% for a perfect model to 0.25 for a non-informative model. For both the bootstrap and cross-validation approaches, Brier scores will be produced as an average for the models that are bootstrapped/cross-validated and will be compared to the Brier score generated from the model developed in the original dataset.
After the internal validation process, we will select model(s) that perform well and calculate the overall sensitivity, specificity, positive predictive value, and negative predictive to assess the accuracy of the model(s) in predicting TBM.
Sensitivity analysis
We will perform the following sensitivity analyses to explore the contributions of risk of bias on the final model(s):
• Exclude studies that investigated all patients for TBM regardless of other CSF findings (co-infection). This is important for discerning which clinical characteristics are predictive of TBM or other meningitis-causing diseases.
• Develop the prediction model(s) with different TBMcase status groupings. The model will be developed with only confirmed TBM and not-TBM cases as per standard practice in predictive model development, but we will also develop model(s) that, for example, group confirmed and probable TBM to see if there's a difference in heterogeneity, clustering, predictive variable selection, and model performance. This is important because shifting the threshold of inclusion or TBM "caseness" could provide further insight into the misclassification of cases as a result of not having poor diagnostic tools for TBM.
• Conduct a misclassification bias analysis. This step is important since there is no "gold-standard" diagnostic criteria for TBM diagnosis so there is likely misclassification bias. Many of the diagnostic methods used to ascertain TBM, such as TB culture in CSF, have known sensitivities and specificities that will be used towards reclassifying cases. Model(s) will be developed with the reclassified case statuses and compared to the model(s) developed with the original case classification.
We will also assess risk of bias and applicability for each included study according to the PROBAST tool for diagnostic accuracy studies 18 . This tool comprises four domains: participant selection, predictor measurement, outcome definition and measurement, and analysis methods. Each domain is assessed in terms of risk of bias, and the first three domains are also assessed in terms of concerns regarding applicability. Signaling questions are included to help judge risk of bias.
Registration
This review is registered with PROSPERO, number CRD42018110501.
Presenting and reporting of results
We will report the results according to the Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data Statement (PRISMA-IPD) 10 . This will include a flow diagram to summarise the study selection process and detail the reasons for exclusion of studies screened as full text. We will publish our search strategy and quality-scoring tool as supplementary documents. Quantitative data will be presented in evidence tables of individual studies as well as in summary tables. We plan to report on quality scores and risk of bias for each eligible study. This may be tabulated and accompanied by narrative summaries. A descriptive analysis of the strength of evidence assessment will be reported. The final prediction model(s), that is, the variable-selected model(s) with the highest area under the receiver operating characteristic curve (AUC), will be implemented in a Smart phone application and a Web-based calculator and graphically depicted using nomograms.
Discussion
TBM is a serious public health concern with delayed diagnosis and treatment being important risk factors for poor outcome 1 . At least 10 attempts have been made to develop clinical prediction models to aid the rapid diagnosis of TBM but none have been broadly successful. The aim of this project is to combine data from multiple sources to develop and internally validate a novel clinical prediction model, which will be made easily available as a smart phone application and a Web-based calculator. By combining data from multiple geographical locations and using advanced machine learning techniques it is hoped that we can develop a model that is broadly generalizable around the world. Further work will involve external validation of the model(s) and testing in randomised controlled trials.
Ethics
No specific ethical approval has been sought for this systematic review. Authors who submit IPD will be asked to confirm that the dissemination of anonymised data was included in the original patient consent document.
Data availability Underlying data
No data is associated with this article. The authors have addressed some of my previous comments. However, there are several points that I have to still query.
Reporting guidelines
Grant information
Firstly, I think there has been some confusion in the use of the terms 'case-mix variation' and heterogeneity. As the project includes an IPD-MA, I was referring to differences in case-mix across studies and heterogeneity in performance studies in line with text in the introduction. Therefore, across some of the changes to the protocol are rather confusing.
If the authors intend to look at heterogeneity in predictor effects, their approach (a stratified intercept model with fixed effect for the predictor effect) will not allow them to investigate this as the predictor effect is fixed. If heterogeneity in predictor effects is of interest, then I would suggest placing a random effect on the predictor effect allowing the slope to change by study and reporting estimates of heterogeneity. If this is not of interest, then please remove mention of investigating heterogeneity in predictor effects.
It is not clear what is meant by '
We will also use this method to assess predictor heterogeneity by HIV status, WHO region, and TB burden within each country'? Do you mean evaluate predictors within subgroups of these factors, fit interactions between predictors and these effects, or something else? I'm also rather confused by the suggestion of classification and regression trees, supervised and unsupervised ML, LCA in relation to case-mix variation. These are just different statistical techniques that can be used to investigate clustering of individuals (by characteristics) and doesn't explicitly say how different studies will be used or what the objective is.
The methods for model development and validation are still vague and suggest to me that the data from multiple studies will be combined and treated as a single dataset rather than as an IPD-MA (accounting for clustering by study). IPD-MA can be very challenging, however there is a lot of guidance on how to conduct them, particularly by T. Debray and R. Riley. Sadly, much of the guidance has either not been considered or been ignored. If using regression modelling, clustering by study could be accounted for by using a random intercept or stratified intercept. It is then also important to decide how the model would be using a random intercept or stratified intercept. It is then also important to decide how the model would be implemented i.e. what intercept would be used for validation in a new study or for new patients in practice (Debray , 2013 )? I am not aware of how clustering can be accounted for when using methods such et al. as CART.
I have some concern about the decision not to impute for missing data, especially given the list of 28 predictors of interest and no minimum sample size that they aim to achieve. In my experience, expecting to receive datasets with 28 predictors of interest is incredibly optimistic. It is more likely that both systematically missing data and partially missing data will be a challenge. If every dataset was missing just one of those variables, there would be no data left to use. It often ends up being a compromise between the number of predictors (and which ones are) considered and the number of datasets included. If then also not imputing for partially missing data, further data is lost and predictor effects may be biased (e.g. only severe cases get certain tests). This could affect your target population and result in models that are not applicable to the population of interest.
Regarding the decision to develop the model in only confirmed TBM and non-TBM patients, I would think that the target population would include probable and possible TBM and therefore there would be an applicability issue if the model was developed using an unrepresentative subgroup of patients (Moons et , 2019 ). These probable and possible cases are also often the individuals in which a prediction model al. has the most potential to be useful. Other options to consider are to include them with one or the other of confirmed TBM and non-TBM so as not to exclude them. Sensitivity may be to change which outcome they're grouped with.
Finally the description of bootstrap validation is not correct. Optimism is not a statistic as such but can be estimated for each performance statistic of interest. The 'optimism-corrected' statistics are then calculated as apparent minus optimism. The optimism for a particular statistic is calculated by repeating the model development in each bootstrap sample, calculating the performance in the bootstrap sample (where it will be optimistic) and also applying that model back to the original dataset (acting as a validation dataset). Repeat lots of times and the average of the differences between these is the estimate of optimism. Estimating optimism by bootstrapping is sufficient, no need to calculate for other validation approaches like IECV. In the introduction the authors mention that case-mix can affect the predictive performance of a model and that big datasets can be used to examine the heterogeneity and improve the predictive performance. However, I don't think they really address this issue in the methods or say how they will use the IPD to try improve the performance. Heterogeneity in performance if the predictor effects are consistent suggests differences in case-mix that are not being captured by the predictors in the model. Unless additional variables that are thought to improve the model are included, how will this be addressed? Will the authors consider recalibrating the baseline risk to different populations for example?
For the risk of bias assessment, I suggest using items from PROBAST too (excluding the analysis domain) which has recently been published and relates to prediction modelling studies (Wolff et al. , 2019 ).
Have the authors considered how much data they would need to acquire to develop new prediction models for TBM e.g. any sample size calculations based on likely event rate and expected number of candidate predictors for consideration in the models, as a target to aim for?
In my experience, one of the biggest difficulties with IPD-MA like these is how different studies record different combinations of variables. Therefore, combining studies for model development can be very difficult and it may be necessary to prioritise certain variables (or combinations of variables) and use a subset of studies with those variables, hence my previous comment regarding sample size. Have the authors considered which variables are of particular interest and what they will do if these are not recorded in individual studies? How will IPD be selected for developing new models as it is unlikely to all be used?
How will missing data be handled? If imputing, will this be done within or across datasets?
It's not clear if one model will be developed or multiple models (using each of the different modelling approaches). If aiming for a single model, how will it be selected?
Bottom of page 5: I'm not sure what is meant by "Model development will initially be carried out 8.
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Bottom of page 5: I'm not sure what is meant by "Model development will initially be carried out using participants with either definite TBM or definitely not TBM. The model will then be applied to participants with possible TBM." Can the authors please clarify? Do they mean that possible TBM will be included in the definition of TBM?
I'm also not sure what is meant by "the training set will be calibrated to optimise the model coefficients for best predictive accuracy using AUC-ROC score" (Data synthesis, part 2)? By definition, the model will be calibrated to the development data and is therefore optimised to the data, which can lead to overfitting.
Will clustering by dataset be accounted for in the model development e.g. using a random intercept?
Will calibration of the model be assessed? This is also likely to be heterogeneous in different populations and therefore may need tailoring to different populations. In contrast, the AUC depends on the case-mix and will be lower in more homogeneous populations which doesn't mean the model doesn't work well.
I don't see the point in splitting each dataset for development and validation, especially when some studies are likely to be small (min. sample size of 10 so even fewer events). The internal-external cross-validation is a better approach as it still retains the external validation element and will help evaluate the heterogeneity in performance across datasets.
Have the authors considered the potential for optimism in model development, particularly if they have few events and small sample size overall? Will they consider shrinking the coefficients (in a regression modelling approach) to correct for optimism?
Data synthesis, part 3: What threshold will be selected to calculate measures of diagnostic test accuracy -will this be based on a predicted probability and pre-specified to avoid bias in using 'optimal' thresholds? I would also suggest evaluating calibration and discrimination as part of the internal validation.
I would suggest reporting according to the TRIPOD guidelines for the multivariable modelling (Collins , 2015 ). et al.
I would caution against simply developing smart phone apps and web-based calculators unless the model demonstrates good predictive ability. Ideally it should be externally validated first before considering it as a tool for use in practice. We would like to thank Professor Snell for her very helpful comments.
Responses drafted by Anna Stadelman.
:
. My responses are below READ ME Comments from Professor Snell are in bold-type font each comment. This is a clear and well-written protocol for a systematic review, collection of IPD and IPD meta-analysis for a new diagnosis model for TBM. I think the aim of the study and details relating to the systematic review part are clear, however I have a few comments/questions for clarity and reproducibility, mostly regarding what happens once IPD has been collected.
1. In the introduction the authors mention that case-mix can affect the predictive performance of a model and that big datasets can be used to examine the heterogeneity and improve the predictive performance. However, I don't think they really address this issue in the methods or say how they will use the IPD to try [to] improve the performance. Heterogeneity in performance if the predictor effects are consistent suggests differences in case-mix that are not being captured by the predictors in the model. Unless additional variables that are thought to improve the model are included, how will this be addressed? Will the authors consider recalibrating the baseline risk to different populations for example?
The objective of assessing heterogeneity will be to ascertain case-mix variation among TBM cases and non-cases to inform model development. To begin, the contributing datasets will be reviewed for sample size, available predictors, and data completeness to inform the selection of a modelling approach. A descriptive analysis will be undertaken to understand similarities and differences between the contributing datasets. Participant characteristics and clinical features will be approach. A descriptive analysis will be undertaken to understand similarities and differences between the contributing datasets. Participant characteristics and clinical features will be summarized for each contributing dataset and compared across datasets using chi-square, t-tests, or non-parametric methods as warranted. Then, we will formally evaluate case-mix variation and predictor heterogeneity via IPD meta-analysis using a logistic regression model with stratified intercepts for each study (99). Each TBM predictor will be rotated into the model individually to underscore the baseline predictive value of each in the different contributing datasets. We will also use this method to assess predictor heterogeneity by HIV status, WHO region, and TB burden within each country. For both the informal (descriptive statistics) and formal (IPD meta-analysis) assessment of heterogeneity, predictor estimates and their uncertainty intervals will be used to determine relative significance as opposed to p-values. Uncertainty intervals for each predictor will indicate how reliable the predictor is in terms of its prediction value. Furthermore, looking at p-values will only assess statistical significance, which may not be clinically meaningful.
Subsequently, we will employ methods of model development that take into account the heterogeneity observed in the IPD meta-analysis. These methods include, but are not limited to, classification and regression trees, supervised and unsupervised machine learning, Latent component analysis, etc. There may be other sources of heterogeneity that become evident during model development which will also be included in the development of the clinical prediction rule.
For the risk of bias assessment, I suggest using items from PROBAST too (excluding the analysis domain) which has recently been published and relates to prediction modelling studies (Wolff , 2019 et al.
).
Thanks for the recommendation.
3. Have the authors considered how much data they would need to acquire to develop new prediction models for TBM e.g. any sample size calculations based on likely event rate and expected number of candidate predictors for consideration in the models, as a target to aim for?
Sample size is difficult to calculate in the context of developing a prediction model. However, the size of the development dataset and number of predictors in the final model have an impact on the statistical power to detect a difference in TBM case vs. non-TBM case. The greater the number of individual participants the more information we have to inform the development of the model, specifically the parameterization of the predictors and variability explained. More data (i.e. individual participants) better optimizes the individual predictors and has a better chance of capturing the variability in TBM case presentations. Ultimately, we will make every effort to acquire as many datasets as possible and limit the number of predictors to the ones that explain the most variability in TBM diagnosis. We have included in the table which variables are of interest in the development of the model(s) (marked with an *). We consider these variables to be the most important for model development and inclusion of data into model development will be contingent on the representation of these variables in the individual contributing datasets. We will conduct a sensitivity analysis with all the individual contributing datasets, regardless of variable inclusion, so as to assess any bias introduced into the model by excluding certain datasets.
5. How will missing data be handled? If imputing, will this be done within or across datasets?
We will not impute any missing data. We will request all the diagnostic data available from investigators and any missingness on an individual level may ultimately end up excluding that particular individual from model development.
It's not clear if one model will be developed or multiple models (using each of the different modelling approaches). If aiming for a single model, how will it be selected?
We will create multiple models with the development dataset and compare the fit across models via bootstrap, k-fold cross validation, and internal-external cross-validation. The model(s) will be developed with confirmed TBM and non-TBM cases, and we will test the model(s) on probable and possible TBM cases as part of the sensitivity analysis.
8. I'm also not sure what is meant by "the training set will be calibrated to optimise the model coefficients for best predictive accuracy using AUC-ROC score" (Data synthesis, part 2)? By definition, the model will be calibrated to the development data and is therefore optimised to the data, which can lead to overfitting.
Sorry for the confusion. Suggested revision in Version 2.0 of the protocol.
9.
Yes, this will be the aim of the IPD meta-analysis. Each predictor of interest will be rotated into a model predicting TBM that has a random intercept for each contributing dataset. The aim of this will be to ascertain heterogeneity in predictor strength, which will be accounted for in the final model(s). However, the overall aim is to develop a model(s) that accounts for heterogeneity by model(s). However, the overall aim is to develop a model(s) that accounts for heterogeneity by region, HIV status, and other known causes of heterogeneity in TBM cases. Therefore, we are hoping that including these predictors in the final model(s) will account for most of the variation in predictor strength that may be introduced by individual contributing datasets.
10.
Yes, model(s) calibration will be assessed and you bring up important points about the metrics for calibration and discrimination.
11. I don't see the point in splitting each dataset for development and validation, especially when some studies are likely to be small (min. sample size of 10 so even fewer events). The internal-external cross-validation is a better approach as it still retains the external validation element and will help evaluate the heterogeneity in performance across datasets.
Agreed. We will revise our internal validation approach to include bootstrap, cross-validation (k-fold), and internal-external validation. Bootstrap validation tells us more about the validity of predictor variable selection in algorithm development, which is useful for assessing how well our predictors assess TBM diagnosis within different samples. Simulations have demonstrated that bootstrap is the best approach to internal validation as it appropriately reflects all sources of model uncertainty, especially in predictor variable selection (113). We will then utilize a k-fold cross-validation approach to assess the validation of the model approach and accuracy of model fit. The resulting c-statistic will convey overall model optimism and accuracy of model fit. The predictive model(s) will be further validated using 'internal-external cross-validation', which is a multiple validation approach that accounts for multiple studies by rotating which are used toward model development and validation (99).
12.
High optimism, indicative of overfitting, can be corrected via shrinkage and we will consider this approach if overfitting is evident. However, we do not anticipate that we will encounter overfitting due to the data reduction step described in Version 2.0 of the protocol.
13. Data synthesis, part 3: What threshold will be selected to calculate measures of diagnostic test accuracy -will this be based on a predicted probability and pre-specified to avoid bias in using 'optimal' thresholds? I would also suggest evaluating calibration and discrimination as part of the internal validation.
We will assess optimism, calibration, and discrimination as part of the internal validation approach and have discussed this process further in Version 2.0 of the protocol. As for determining a and have discussed this process further in Version 2.0 of the protocol. As for determining a pre-specified predictive threshold for defining TBM versus not, there is little information in the literature to inform an appropriate cutoff for TBM. Prior prediction models have used ROC curve to determine an optimal cutoff. Furthermore, this is the first study to include data from different populations world-wide. As such it is difficult to pre-specify the optimal predictive cutoff.
14. I would suggest reporting according to the TRIPOD guidelines for the multivariable modelling (Collins , 2015 et al.
Great! Thanks for the recommendation.
15. I would caution against simply developing smart phone apps and web-based calculators unless the model demonstrates good predictive ability. Ideally it should be externally validated first before considering it as a tool for use in practice.
bacteriologically confirm the diagnosis of tuberculous meningitis.
In developing countries and countries with a very high tuberculosis burden, tuberculous meningitis is encountered very frequently. Tuberculous meningitis is the commonest CNS infection seen in Neurology and Medicine indoors. Facing resource constrains, we always have to rely on clinical, imaging and cerebrospinal fluid parameters. Despite constrains, we are able to make reliable diagnosis of tuberculous meningitis most of the time. Our classical teaching points, to diagnose tuberculous meningitis, are often accurate. With a clinical diagnosis of meningitis along with characteristic cerebrospinal fluid findings help in making reasonable and prompt diagnosis enabling to start antituberculosis treatment with confidence. Raised cerebrospinal fluid lymphocyte count and markedly raised protein are characteristically seen in tuberculous meningitis.
Certain clinical signs are very specific to tuberculous meningitis. For example, sixth nerve involvement and vision loss in points towards a basal meningeal involvement and tuberculous meningitis. Other cranial nerve involvements are very infrequent. In patients with multiple cranial nerve palsies, fungal infection and a malignancy are more likely possibilities. As per observation, headache and fever are often not dominant features, and they are never presenting features. Similarly, neck rigidity may not be present in many patients. In cryptococcal meningitis, severe and dominant headache may be a presenting feature. Presence of extrapyramidal movements is a rare manifestation of tuberculous meningitis in adults.
Extrapyramidal movements are more frequent in children. Diagnostic caution is exercised in elderly patients and HIV infected patients. In these two groups, there are high chances of alternative diagnosis. We routinely perform tests with India ink preparation and detection of malignant cells. Still, distinctive features of tuberculous meningitis help in diagnosis of tuberculous meningitis in these two populations as well. Aspergillosis has a more aggressive course and large vessel involvement is more common. In tuberculous meningitis infarcts are usually small and periventricular.
Another issue that need to be addressed is diagnosis of drug-resistant tuberculous meningitis. XpertMTB/RIF test, which is now readily available, start discovering drug-resistant tuberculous meningitis in increasing number. This is not surprising because India harbors the major portion of global drug-resistant tuberculosis problems. This issue also needs to be given due emphasis.
I greatly appreciate the investigators efforts to evolve a predictive logistic model to accurately diagnose definite tuberculous meningitis. There are certain points that I highlighted that need to be re-looked and can be incorporated in this protocol.
